Skip to main content
    A

    Ardelyx Inc (ARDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.19
    +0.07 (+2.24%)

    Market Cap: $805.54M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(26/39)
    Avg Surprise
    +99.17%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.06 - $0.02
    8 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.04-136.3%
    60d ago$0.04-138.9%
    30d ago$-0.02+18.8%
    7d ago$-0.01-9.4%
    Current$-0.02
    Revenue Consensus
    $129M
    Range$120M - $135M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.02
    Range$-0.05 - $0.11
    8 analysts
    Revenue Consensus
    $146M
    Range$132M - $160M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 6
    		$-0.07$-0.05-40.00%Miss+12.5%
    Mar 26
    Reported Apr 30
    		$-0.15$-0.14-7.14%Miss+11.8%
    Dec 25
    Reported Feb 19
    		$-0.00N/A+91.37%Beat-108.5%
    Sep 25
    Reported Oct 30
    		$-0.00N/A+94.29%Beat-17.6%
    Jun 25
    Reported Aug 4
    		$-0.08$-0.14+42.86%Beat-14.3%
    Mar 25
    Reported May 1
    		$-0.17$-0.07-142.86%Miss-54.5%
    Dec 24
    Reported Feb 20
    		$0.02$-0.00+2957.14%Beat+116.7%
    Sep 24
    Reported Oct 31
    		$-0.00N/A+93.20%Beat-111.3%
    Jun 24
    Reported Aug 1
    		$-0.07$-0.11+36.36%Beat+12.5%
    Mar 24
    Reported May 2
    		$-0.11$-0.16+31.25%Beat+15.4%
    Dec 23
    Reported Feb 22
    		$-0.12$-0.09-33.33%Miss-300.0%
    Sep 23
    Reported Oct 31
    		$0.03N/A+127.27%Beat+121.4%
    Jun 23
    Reported Aug 2
    		$-0.08$-0.11+27.27%Beat+57.9%
    Mar 23
    Reported May 3
    		$-0.13$-0.10-30.00%Miss+38.1%
    Dec 22
    Reported Mar 2
    		$0.06$-0.02+400.00%Beat+119.4%
    Sep 22
    Reported Nov 3
    		$-0.14$-0.17+17.65%Beat+66.7%
    Jun 22
    Reported Aug 4
    		$-0.19$-0.20+5.00%Beat+57.8%
    Mar 22
    Reported May 5
    		$-0.21$-0.23+8.70%Beat+38.2%
    Dec 21
    Reported Feb 28
    		$-0.31$-0.30-3.33%Miss+3.1%
    Sep 21
    Reported Nov 12
    		$-0.42$-0.35-20.00%Miss-110.0%
    Jun 21
    Reported Aug 13
    		$-0.45$-0.37-21.62%Miss-60.7%
    Mar 21
    Reported May 6
    		$-0.34$-0.34+0.00%Beat-36.0%
    Dec 20
    Reported Mar 8
    		$-0.32$-0.26-23.08%Miss-18.5%
    Sep 20
    Reported Nov 5
    		$-0.20$-0.30+33.33%Beat+45.9%
    Jun 20
    Reported Aug 6
    		$-0.28$-0.25-12.00%Miss+31.7%
    Mar 20
    Reported May 7
    		$-0.25$-0.25+0.00%Beat+40.5%
    Dec 19
    Reported Mar 6
    		$-0.27$-0.33+18.18%Beat+40.0%
    Sep 19
    Reported Nov 6
    		$-0.37$-0.37+0.00%Beat+5.1%
    Jun 19
    Reported Aug 9
    		$-0.41$-0.38-7.89%Miss+2.4%
    Mar 19
    Reported May 7
    		$-0.42$-0.39-7.69%Miss-16.7%
    Dec 18
    Reported Mar 6
    		$-0.45$-0.41-9.76%Miss-314.3%
    Sep 18
    Reported Nov 7
    		$-0.39$-0.43+9.30%Beat+11.4%
    Jun 18
    Reported Aug 7
    		$-0.42$-0.44+4.55%Beat+22.2%
    Mar 18
    Reported May 8
    		$-0.36$-0.46+21.74%Beat+39.0%
    Dec 17
    Reported Mar 14
    		$0.21$-0.41+151.22%Beat+131.8%
    Sep 17
    Reported Nov 7
    		$-0.44$-0.54+18.52%Beat-
    Jun 17
    Reported Aug 9
    		$-0.54$-0.65+16.92%Beat-
    Mar 17
    Reported May 5
    		$-0.59$-0.67+11.94%Beat-
    Dec 16
    Reported Feb 17
    		$-0.66$-0.72+8.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-14.13EV/EBITDAN/A
    Price/FCF-44.16xFCF Yield-2.26%
    Profitability
    Profit Margin-12.30%Operating Margin-10.30%
    ROE-38.60%ROIC-6.68%
    Financial Health
    Debt/Equity1.69xInterest Coverage-0.93x
    Current Ratio3.34xQuick Ratio3.15x
    Trading Statistics
    Beta0.68Avg Volume4.57M
    52-Week High$8.4052-Week Low$3.06

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.28
    SMA 20$3.36
    SMA 50$3.67
    SMA 200$5.53
    EMA 10$3.27
    EMA 20$3.37
    EMA 50$3.77
    EMA 200$4.93

    MACD

    Line: -0.15Signal: -0.16Hist: 0.01

    ADX

    ADX: 41.5+DI: 9.5-DI: 23.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$3.37

    Bollinger Bands

    Upper Band$3.60
    Lower Band$3.13
    %B Position1381%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    32.0

    Momentum Oscillators

    Stoch %K16.5
    Stoch %D16.0
    Williams %R-69.4
    ROC (10d)-6.7%
    Momentum-0.23
    CCI (20d)-144.4
    MFI (14d)26.7

    Volatility Measures

    ATR (14d)$0.13(4.2%)
    StdDev (20d)0.12
    Hist Vol29.8%(Moderate)

    Volume Flow

    VWAP$3.17
    OBV-17.0M
    AD Line-89.2M
    CMF (20d)0.067

    Volume Metrics

    Avg Vol (20d)4.5M
    Vol Ratio1.3x
    VWMA (20d)$3.35

    Pivot Points

    R3$3.30
    R2$3.25
    R1$3.19
    Pivot Point$3.14
    S1$3.07
    S2$3.02
    S3$2.96

    Advanced Oscillators

    TSI-38.45
    Ultimate Osc51.3
    KST-104.19

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$120.88M$94.47M$125.22M$110.33M$97.66M$74.11M$116.13M$98.24M$73.22M$46.02M$34.36M$56.39M
    Cost of Revenue$5.76M$4.81M$10.85M$3.98M$12.40M$12.30M$18.26M$15.73M$9.44M$7.13M$5.08M$7.69M
    Gross Profit$115.12M$89.66M$114.37M$106.35M$85.26M$61.81M$97.86M$82.51M$63.79M$38.90M$29.29M$48.70M
    Operating Expenses$127.54M$122.45M$109.27M$101.68M$99.65M$98.16M$89.74M$80.28M$77.42M$63.57M$57.27M$41.30M
    R&D$26.10M$20.19M$22.86M$18.07M$15.67M$14.94M$13.67M$15.31M$12.76M$10.58M$9.52M$8.64M
    SG&A$101.44M$102.27M$86.41M$83.61M$83.99M$83.22M$76.07M$64.97M$64.65M$52.99M$47.75M$32.66M
    Operating Income$-12,425,000$-32,793,000$5.10M$4.67M$-14,395,000$-36,349,000$8.13M$2.23M$-13,630,000$-24,678,000$-27,986,000$7.40M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$6.22M$6.92M$7.58M$7.98M$6.58M$6.26M$5.85M$5.28M$4.90M$4.06M$2.81M$2.03M
    Income Before Tax$-16,611,000$-37,597,000$-400,000$-867,000$-19,078,000$-40,285,000$4.68M$-766,000$-16,387,000$-26,397,000$-28,469,000$6.83M
    Income Tax Expense$110,000$8,000$7,000$102,000$1,000$859,000$35,000$43,000$67,000$121,000$333,000$200,000
    Net Income$-16,721,000$-37,605,000$-407,000$-969,000$-19,079,000$-41,144,000$4.64M$-809,000$-16,454,000$-26,518,000$-28,802,000$6.63M
    EBITDA$-8,215,000$-28,184,000$10.18M$10.47M$-9,583,000$-31,285,000$13.03M$7.07M$-9,258,000$-20,151,000$-24,175,000$8.33M
    EBIT$-10,387,000$-30,681,000$7.18M$7.12M$-12,503,000$-34,023,000$10.53M$4.51M$-11,485,000$-22,339,000$-25,664,000$8.86M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARDX

    Government Contracts

    Gov Obligations (TTM)
    $19777
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    9
    New Awards (TTM)
    8
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24526N0689Department of Veterans AffairsDepartment of Veterans Affairs$11948Jun 26, 2026
    36C24526N0339Department of Veterans AffairsDepartment of Veterans Affairs$11948Feb 20, 2026
    36C24526N0650Department of Veterans AffairsDepartment of Veterans Affairs$3999Jun 12, 2026
    36C24526N0202Department of Veterans AffairsDepartment of Veterans Affairs$2017Dec 31, 2025
    36C26125F0504Department of Veterans AffairsDepartment of Veterans Affairs$2017Sep 25, 2025
    36C24525N1015Department of Veterans AffairsDepartment of Veterans Affairs$2017Sep 19, 2025
    36C24526N0688Department of Veterans AffairsDepartment of Veterans Affairs$1991Jun 26, 2026
    36C24526N0497Department of Veterans AffairsDepartment of Veterans Affairs$1991Apr 9, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6...

    GlobeNewswire•10/15/26•Bearish

    Ardelyx Files $520k Lobbying Report for Third Quarter

    Ardelyx Inc. filed its third-quarter 2026 in-house lobbying disclosure, reporting $520,000 spent on issues like Medicare End-Stage Renal Disease (ESRD) pharmaceutical access and reimbursement. This filing comes as...

    Legis1•10/15/26•Neutral

    ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

    SueWallSt.com has issued a shareholder alert for Ardelyx, Inc. (NASDAQ: ARDX) investors regarding a securities class action lawsuit. The lawsuit alleges that Ardelyx misled investors about potential peak sales for its...

    PR Newswire•10/15/26•Bearish

    US High Growth Tech Stocks to Watch for Potential Portfolio Boost

    Despite a recent market drop, the US market shows annual growth and anticipated earnings increases, making high-growth tech stocks appealing. This article highlights three biopharmaceutical companies—Ardelyx...

    Simply Wall Street•10/15/26•Neutral

    ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses

    Robbins LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased stock between January 13, 2025, and August 6...

    Morningstar•10/14/26•Bearish

    ARDX Valuation and Fair Value

    P/E
    -14.1x
    Forward P/E
    9.9x
    P/FCF
    -44.2x
    PEG
    -0.1x
    P/B
    5.3x
    See GNG's fair value

    ARDX Profitability: Margins, ROIC and FCF

    Gross margin
    94.4%
    Operating margin
    -10.3%
    Net margin
    -12.3%
    ROIC
    -6.7%
    ROE
    -38.6%
    FCF margin
    -4.0%
    FCF yield
    -2.3%

    ARDX Competitors

    CompanyTicker
    P3 Health Partners IncPIII
    Esperion Therapeutics IncESPR
    InMode LtdINMD
    Ginkgo Bioworks HoldingsDNA
    Monte Rosa Therapeutics IncGLUE
    Corvus Pharmaceuticals IncCRVS
    Cullinan Oncology LLCCGEM
    Varex Imaging CorpVREX

    Sector: Healthcare

    ARDX Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    1
    Buy
    10
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ARDX Bull Case vs Bear Case

    Bull case

    • ARDX grew quarterly revenue 23.8% year over year.
    • 100.0% of ARDX's analyst ratings are Buy or Strong Buy.

    Bear case

    • ARDX has a -12.3% net profit margin.

    ARDX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    386.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About ARDX

    Does ARDX pay dividends?

    Ardelyx Inc (ARDX) does not currently pay a regular dividend.

    What is ARDX's market cap?

    Ardelyx Inc (ARDX) has a market capitalization of $805.54M with a current stock price of $3.19.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In